HCA Healthcare, Inc. (HCA) reported first-quarter 2025 adjusted earnings per share (EPS) of $6.45, which outpaced the Zacks Consensus Estimate of $5.77. The bottom line advanced 20.3% year over year. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Revenues rose 5.7% year over year to $18.3 billion. The top line beat the consensus mark by 0.1%.The strong first-quarter results benefited from higher patient volumes, which led to an increased number of inpatient surgeries, emergency room v ...

HCA Healthcare, Inc. (NYSE:HCA) Q1 2025 Earnings Conference Call April 25, 2025 10:00 AM ET Company Participants Frank Morgan - Vice President of Investor Relations Sam Hazen - Chief Executive Officer Mike Marks - Chief Financial Officer Conference Call Participants Ann Hynes - Mizuho Securities Pito Chickering - Deutsche Bank A.J. Rice - UBS Whit Mayo - Leerink Partners Ben Hendrix - RBC Capital Markets Sarah James - Cantor Fitzgerald Brian Tanquilut - Jefferies Andrew Mok - Barclays Capital Matthew Gillmo ...

HCA Healthcare (HCA) reported $18.32 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 5.7%. EPS of $6.45 for the same period compares to $5.36 a year ago.The reported revenue represents a surprise of +0.08% over the Zacks Consensus Estimate of $18.31 billion. With the consensus EPS estimate being $5.77, the EPS surprise was +11.79%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determi ...

HCA Healthcare (HCA) came out with quarterly earnings of $6.45 per share, beating the Zacks Consensus Estimate of $5.77 per share. This compares to earnings of $5.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.79%. A quarter ago, it was expected that this hospital operator would post earnings of $5.97 per share when it actually produced earnings of $6.22, delivering a surprise of 4.19%.Over the last four quarters, the c ...

HCA Healthcare delivered a strong first quarter, beating expectations in both earnings and revenue.HCA Healthcare (HCA 1.64%), a prominent player in the healthcare sector, announced robust first-quarter results for 2025 on Friday, April 25, that surpassed market expectations. The company recorded an adjusted EPS of $6.45 for Q1 2025, exceeding the anticipated $5.75. Its reported revenue was $18.32 billion, slightly above the expected $18.26 billion.MetricQ1 2025Analysts' EstimateQ1 2024Change (YOY)Adjusted ...

Exhibit 99.1 For the first quarter of 2025, Adjusted EBITDA totaled $3.733 billion, compared to $3.353 billion in the first quarter of 2024. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release. Same facility admissions increased 2.6 percent and same facility equivalent admissions increased 2.8 percent in the first quarter of 2025, compared ...

Group 1: Earnings Estimates - HCA Healthcare is expected to report first-quarter 2025 earnings of $5.77 per share on revenues of $18.31 billion, indicating a year-over-year earnings growth of 7.7% and revenue growth of 5.6% [1][2] - For the full year 2025, the revenue estimate is $74.69 billion, reflecting a 5.8% increase year-over-year, while the EPS estimate is $24.98, implying a 13.8% increase year-over-year [2] Group 2: Recent Performance - HCA Healthcare has consistently beaten earnings estimates in the last four quarters, with an average surprise of 5.9% [2] - The company has an Earnings ESP of 0.00% and a Zacks Rank of 3 (Hold), indicating uncertainty regarding an earnings beat for the upcoming quarter [3] Group 3: Operational Metrics - The consensus estimate for equivalent admissions shows a 3.4% year-over-year growth, while the model predicts a 3.5% increase; revenue per equivalent admission is expected to rise by 2% [5] - Equivalent patient days are estimated to grow by 1.8% year-over-year, but rising expenses and lower occupancy rates pose challenges [6] Group 4: Expense and Occupancy Trends - Total operating expenses are projected to increase by 5.8% year-over-year, driven by higher salaries, benefits, and supply costs, with supply costs expected to rise nearly 8% [7] - The occupancy rate is estimated at 72.68%, down from 75.20% a year ago, and the average length of stay is expected to decline by 2.4% [7]

Wall Street analysts expect HCA Healthcare (HCA) to post quarterly earnings of $5.77 per share in its upcoming report, which indicates a year-over-year increase of 7.7%. Revenues are expected to be $18.31 billion, up 5.6% from the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Ahead of a company's earnings disclosure, ...

Core Insights - The article discusses an investment service and community focused on the oil and natural gas sector, emphasizing cash flow and the potential for value and growth in this industry [1]. Group 1: Investment Service Features - The service offers subscribers access to a model account with over 50 stocks, detailed cash flow analyses of exploration and production (E&P) firms, and live chat discussions about the sector [2]. - A promotional offer is available for a two-week free trial, encouraging new users to explore opportunities in the oil and gas market [3].

Is a recession coming? Our economic outlook seems increasingly gloomy due to President Trump's trade policies. Though things might not go that far, it's still worth planning ahead.If a recession does hit, it might also affect the stock market, and different companies and sectors will perform differently. Let's consider two stocks that should handle recessions better than most and are worth investing in for the long haul: Vertex Pharmaceuticals (VRTX -2.01%) and HCA Healthcare (HCA -4.78%).1. Vertex Pharmace ...